Roche today will provide an
update on its leading late-stage pipeline comprising twelve new molecular
entities in key therapeutic areas. The London
investor event will focus on major progress that has been achieved in recent
months with Roche’s late-stage pipeline assets in the areas of oncology and
CNS, as well as on further development plans of these potential breakthrough
medicines.
“Our goal is to continue delivering innovative medicines in
therapeutic areas of high unmet need and to bring true medical value to
patients. I am pleased that the glycine reuptake inhibitor and ocrelizumab –
two molecules with the potential to treat severe diseases such as schizophrenia
or multiple sclerosis are progressing to late-stage development”, said Hal
Barron, M.D., Head of Global Product Development and
Chief Medical Officer of Roche. “We also see that the
concept of Personalized Healthcare is becoming a reality for more and more of
our development projects. MetMAb and the BRAF inhibitor are two encouraging
examples for how personalized therapy could improve outcomes in lung cancer and
melanoma, respectively.”
Roche’s late-stage pipeline is progressing well with
potentially ten regulatory submissions of new molecular entities until the end
of 2013. Pipeline molecules such as T-DM1 and pertuzumab in breast cancer, GA101/RG7159
in NHL1 and CLL2 or the BRAF inhibitor RG7204 in melanoma are designed to move
the standard of care in treating these diseases and improve the chances of
longer survival or even cure. Other molecules such as the glycine reuptake
inhibitor RG1678 and ocrelizumab RG1594 have the potential to improve outcomes
in diseases such as schizophrenia or multiple sclerosis where new therapies are
urgently needed.
